FocalTherics at H.C. Wainwright conference: growth, new uses

FocalTherics reported Q2 2026 HIFU revenue growth of 39%, Focal One system-sales growth of 44%, U.S. procedure growth of 47%, and gross margin expansion to 55.6%, with its installed base reaching 184 systems. Management targets roughly 40% revenue CAGR and 60% gross margin over the next three years, aiming for operating breakeven and positive EBITDA by 2028, although trailing EBITDA remains negative at $23.67M. Growth catalysts include a proposed 11.6% Medicare reimbursement increase for January 2027, BPH and endometriosis clinical-data milestones, and expansion into international markets, while execution toward profitability remains the key risk.

Analysis

FOCL's investment case is now a capital-efficiency test rather than a pure adoption story. At roughly $79M of trailing revenue and negative EBITDA, the implied 2028 profitability target requires not only sustained system placements but a rising mix of recurring procedure/service revenue to absorb commercial, clinical, and international-expansion costs. The key underwriting variable is revenue per installed system: if procedure growth remains materially ahead of installed-base growth for the next 2-3 quarters, utilization-driven operating leverage is credible; if placements lead procedures, the company risks becoming a lower-margin capital-equipment vendor with recurring dilution risk.

The proposed reimbursement uplift is more important for hospital purchase ROI than for FOCL's direct pricing, and could shorten sales cycles at systems already operating mobile programs. HCA is a modest second-order beneficiary only if higher reimbursement and utilization convert into broader network deployment; FOCL is too small to affect HCA earnings. More consequentially, reimbursement validation may attract better-capitalized urology and surgical-robotics competitors, raising sales-and-marketing intensity before FOCL reaches scale and limiting the assumed margin expansion.

Near-term upside rests on H2 execution, randomized clinical publications, and BPH/endometriosis data, but the latter should not be capitalized as meaningful revenue before regulatory and payer conversion. The market is likely assigning platform optionality to indications with uncertain commercialization timing, while the stated long-dated profitability goal leaves substantial financing risk if cash burn does not decline by 2027. A weak system-sales quarter, procedure-utilization slowdown, unfavorable final reimbursement rule, or an EBITDA-loss trajectory that fails to narrow would challenge the thesis quickly.

Key Decisions for Investors

• Maintain FOCL as a small, event-driven long/watch position only; add after the next earnings release if U.S. procedure growth remains above 35%, gross margin holds above 53%, and operating-loss dollars narrow sequentially. Target a 6-12 month rerating on recurring-revenue evidence; exit on gross margin below 50% or a material cut to the 2028 breakeven framework.
• Do not underwrite BPH or endometriosis as base-case value until data quality, regulatory pathway, and payer coverage are independently disclosed. Set alerts for late-2026 clinical readouts and the final January 2027 Medicare rule; favorable outcomes are potential catalysts, while delays should be treated as a reason to reduce exposure rather than average down.
• Avoid using HCA as a direct read-through trade. For a healthcare-services expression of outpatient procedure reimbursement strength, monitor HCA's capital-spending and ambulatory-care commentary, but FOCL system purchases are immaterial to consolidated results.
• For investors able to trade illiquid small-cap volatility, prefer staged equity entry over long-dated calls: FOCL's binary clinical and financing exposure makes option pricing and liquidity likely unattractive. Size for a high-volatility outcome, with upside contingent on utilization conversion rather than management's TAM framing.